Antiviral Compounds with Broad Neutralization Capabilities
Description of Invention:
The NIH is pleased to announce as available for licensing a technology that provides for novel antiviral compounds effective against a broad spectrum of viruses. The compounds utilize soluble phospholipases, exemplified by PLA2-X and others, either alone or as a fusion protein with a viral binding polypeptide. These compositions are able to inactivate viruses through enzymatic degradation of the viral membrane without affecting target cells of infection. The potential broad application of these compounds could address a significant health need for effective antivirals.
Applications:
This technology provides compositions and methods for the treatment of viral infection and has human and veterinary applications.
Advantages:
The compounds described by the current technology are not necessarily specific for a type of virus or viral strain like many currently available antiviral compounds, and therefore have broad therapeutic antiviral applications. Further, virions resistant to damage by antibody and complement have been shown to be lysed by compounds of the invention suggesting antiviral surveillance independent of a humoral immune response.
Development Status:
Proof of concept in vitro studies using human cells have shown antiviral activity with viruses’ pseudotyped with envelope proteins from Ebola, HIV, Marburg and MoMuLV.
Inventors:
Gary J. Nabel and Jae Ouk Kim (VRC/NIAID)
Patent Status:
DHHS Reference No. E-013-2006/1 --
PCT Application No. PCT/US2007/004471 filed 21 Feb 2007, which published as WO 2008/048348 on 24 Apr 2008
U.S. Patent Application No. 12/224,273 filed 21 Aug 2008
Relevant Publication: J-O Kim et al. Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2. J Virol. 2007 Feb;81(3):1444-1450. [PubMed abs]
Licensing Status: Available for exclusive or non-exclusive licensing.
For Additional Information Please Contact: Cristina Thalhammer-Reyero PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4507
Email: thalhamc@mail.nih.gov
Fax: (301) 402-0220
